SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM). Hematologic malignancies are cancers of the blood and lymph systems. Today’s virtual session brought together global experts and key opinion leaders who shared new data demonstrating how OGM is reshaping cytogenetic and molecular workflows by detecting critical structural var ...

Core Insights - Artelo Biosciences, Inc. is advancing its clinical-stage pharmaceutical programs with positive human data and upcoming clinical catalysts, focusing on treatments for cancer, pain, and other conditions [1] Business Highlights - Successful completion of a Phase 1 study for ART26.12, showing a favorable safety profile and predictable pharmacokinetics, with plans to initiate a multiple ascending dose study in Q3 2026 [2] - Positive interim Phase 2 results for ART27.13, demonstrating improvements in body weight, lean body mass, and physical activity in patients with cancer anorexia-cachexia syndrome [3] - Received favorable regulatory guidance from the UK MHRA for ART12.11, with plans to initiate human clinical studies in H1 2027 [4] Clinical Progress - ART26.12 has shown sustained analgesic effects comparable to naproxen without tolerance in preclinical models, positioning it as a non-opioid alternative for pain management [5] - ART27.13 has received a Notice of Allowance from the European Patent Office, extending patent protection through December 2041, which has increased partner interest in its development [5] - ART12.11 has demonstrated robust antidepressant-like activity in preclinical studies, with plans for first-in-human studies early next year [5] Financial Results - Research and development expenses for FY 2025 were $5.4 million, down from $6.0 million in FY 2024 [6] - General and administrative expenses increased to $6.0 million in FY 2025 from $4.1 million in the previous year [6] - The net loss for FY 2025 was $12.9 million, or $12.52 per share, compared to a net loss of $9.8 million in FY 2024 [6] - Cash and investments totaled $0.6 million as of December 31, 2025 [6] Product Information - ART26.12 is a lead FABP5 inhibitor aimed at treating chemotherapy-induced peripheral neuropathy, with a favorable safety profile and dosing flexibility [8] - ART27.13 is a cannabinoid receptor agonist targeting cancer-related anorexia and cachexia, showing a mean weight gain of over 6% in the top dose group compared to a 5% loss in the placebo group [9][10] - ART12.11 is a proprietary cocrystal composition of CBD and TMP, with enhanced pharmacokinetics and plans for clinical studies in 2026 [11]

Core Insights - Clene Inc. is focused on developing treatments for neurodegenerative diseases, particularly ALS, through its investigational drug CNM-Au8, with key regulatory and clinical milestones anticipated in 2026 [1][2] Financial Position - The company completed an oversubscribed registered direct offering of over $28 million in January 2026, providing sufficient cash to fund operations into the fourth quarter of 2026 [4][7] - Additional financing tranches totaling over $22 million are structured to align with NDA acceptance and FDA approval milestones, expected to support operations into 2027 [4] Regulatory Steps and Clinical Milestones - Clene has engaged with the FDA regarding CNM-Au8, with an in-person Type C meeting scheduled by the end of Q1 2026 to discuss data submitted in late 2025 [5][7] - The company plans to submit a New Drug Application (NDA) for CNM-Au8 via an accelerated regulatory pathway in Q2 2026, with potential FDA acceptance and PDUFA date issuance in the second half of 2026 [5][7] Clinical Data and Efficacy - CNM-Au8 has shown prolonged survival in ALS patients, with a median life expectancy of 2-4 years post-diagnosis, and demonstrated statistically significant reductions in mortality risk and clinical worsening [6][8] - The treatment has also shown favorable safety and tolerability, with no serious adverse events reported across over 1,000 patient years of treatment [9] Future Trials - A confirmatory Phase 3 RESTORE-ALS trial is planned to begin later in 2026 to further evaluate the survival benefit of CNM-Au8 [10] Broader Pipeline - CNM-Au8 is also being explored for potential benefits in multiple sclerosis (MS) and Parkinson's disease, with plans to finalize Phase 3 clinical trial designs for MS in 2026 [12]

Core Viewpoint - Erasca, Inc. has received a patent for ERAS-4001, a pan-KRAS inhibitor, providing intellectual property protection until at least 2043, which strengthens its position in the RAS-driven cancer market [1][2] Group 1: Intellectual Property and Pipeline - The newly issued U.S. patent enhances the ERAS-4001 program and supports the company's diversified intellectual property strategy in RAS-driven cancers [2] - The patent protection for ERAS-4001 extends through at least 2043, with additional patents pending, providing a robust long-term IP foundation [2] - Initial Phase 1 monotherapy data for ERAS-0015 is expected in the first half of 2026, while data for ERAS-4001 is anticipated in the second half of 2026 [1] Group 2: Product Details - ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor currently being evaluated in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors [3] - Preclinical studies show ERAS-4001 has favorable potency against KRAS G12X mutations and wildtype amplifications, with no activity against HRAS or NRAS wildtype proteins [3] - ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS-1 Phase 1 trial, demonstrating favorable safety and tolerability, with early data showing responses in multiple patients [4] Group 3: Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company's mission is to "erase cancer" through novel therapies and combination regimens targeting the RAS/MAPK pathway [5]

• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability Nautilus Voyager™ Platform SEATTLE, Feb. 24, 2026 (GLO ...

Diginex deepens engagement with ADGM’s sustainable finance ecosystem, aligning with a network of 170+ financial institutions and corporate signatories. Diginex is focused on supporting organizations preparing for compliance with the UAE Federal Climate Law (effective May 30, 2025 with reporting obligations due May 30, 2026), addressing growing demand for emissions measurement, reporting and transition planning solutions. ABU DHABI, United Arab Emirates, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diginex Limited (NAS ...

SOUTHLAKE, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Renewal Fuels, Inc. (OTC: RNWF) (“RNWF”, “American Fusion” or the “Company”), today announced the appointment of Fabrice David as an Independent Director of the Company, effective February 23, 2026. Mr. David is an independent scientific researcher, inventor, and strategic advisor with more than two decades of experience spanning fusion-related energy science, advanced nuclear phenomena, propulsion systems, and applied biotechnology. He has authored or co- ...

ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours ...

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be participating in the upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat Time: 1:10 p.m. ETLocation: Boston, MA Leerink Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 8:40 a ...

Baker Hughes to provide 25 BRUSH™ Power Generation DAX 7 generators to complement Boom’s 42-megawatt Superpower aeroderivative turbinesCombined power equipment will support Boom’s 1.21-gigawatt commitment to Crusoe for critical AI data center infrastructure HOUSTON and LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR), an energy technology company, announced Tuesday an award to supply 25 BRUSH™ Power Generation electric generators, along with Automatic Voltage Regulators (AVRs) and cubicl ...